Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/31891

Full metadata record
DC FieldValueLanguage
dc.contributor.authorCosta, A. R.por
dc.contributor.authorRodrigues, E.por
dc.contributor.authorHenriques, Marianapor
dc.contributor.authorOliveira, Rosáriopor
dc.contributor.authorAzeredo, Joanapor
dc.date.accessioned2014-12-11T18:43:56Z-
dc.date.available2014-12-11T18:43:56Z-
dc.date.issued2014-
dc.identifier.issn0738-8551por
dc.identifier.urihttp://hdl.handle.net/1822/31891-
dc.description.abstractThe emergence of the biopharmaceutical industry represented a major revolution for modern medicine, through the development of recombinant therapeutic proteins that brought new hope for many patients with previously untreatable diseases. The ever-growing demand for these therapeutics forces a constant technological evolution to increase product yields while simultaneously reducing costs. However, the process changes made for this purpose may also affect the quality of the product, a factor that was initially overlooked but which is now a major focus of concern. Of the many properties determining product quality, glycosylation is regarded as one of the most important, influencing, for example, the biological activity, serum half-life and immunogenicity of the protein. Consequently, monitoring and control of glycosylation is now critical in biopharmaceutical manufacturing and a requirement of regulatory agencies. A rapid evolution is being observed in this context, concerning the influence of glycosylation in the efficacy of different therapeutic proteins, the impact on glycosylation of a diversity of parameters/processes involved in therapeutic protein production, the analytical methodologies employed for glycosylation monitoring and control, as well as strategies that are being explored to use this property to improve therapeutic protein efficacy (glycoengineering). The present work reviews the main findings on these subjects, providing an up-to-date source of information to support further studies.por
dc.description.sponsorshipThis work was financially supported by the Portuguese Foundation for Science and Technology (FCT), with grants SFRH/BD/46660/2008 for Ana Rita Costa and SFRH/BD/46661/2008 for Maria Elisa Rodrigues.por
dc.language.isoengpor
dc.publisherInforma Healthcarepor
dc.rightsrestrictedAccesspor
dc.subjectAnalytical methodologiespor
dc.subjectCulture parameterspor
dc.subjectExpression systempor
dc.subjectGlycoengineeringpor
dc.subjectMammalian cellspor
dc.subjectProcess developmentpor
dc.titleGlycosylation: impact, control and improvement during therapeutic protein productionpor
dc.typearticle-
dc.peerreviewedyespor
dc.relation.publisherversionhttp://informahealthcare.com/journal/btypor
dc.commentsCEB14760por
sdum.publicationstatuspublishedpor
degois.publication.firstPage281por
degois.publication.lastPage299por
degois.publication.issue4por
degois.publication.locationUnited Kingdom-
degois.publication.titleCritical Reviews in Biotechnologypor
degois.publication.volume34por
dc.date.updated2014-12-01T11:07:23Z-
dc.identifier.essn1549-7801-
dc.identifier.doi10.3109/07388551.2013.793649por
dc.identifier.pmid23919242por
dc.subject.wosScience & Technologypor
sdum.journalCritical Reviews in Biotechnologypor
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_14760_1.pdf
  Restricted access
622,17 kBAdobe PDFView/Open    Request a copy!

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID